IMMUNOCLIN CORP (IMCL)

0.16
OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
Health Winners & Losers: Amylin

Health Winners & Losers: Amylin

Gains by Cephalon and Genzyme help boost the Amex biotech index. Amylin shares fall 1.7% after talks about pancreatitis and diabetes drug Byetta.

Health Winners & Losers: Medivation

Shares of Medivation surge after announcing a major marketing deal with Pfizer.

Three Biotech Stocks That Could Double

Biotech is back, and here are some ways to play it.

Health Winners & Losers: Noven

Shares fall as a voluntary recall of two lots of Daytrana is issued.

King Bids $1.4 Billion for Alpharma

King Bids $1.4 Billion for Alpharma

The drugmaker is the latest to go shopping in a deal-happy summer.

Biotech-Stock Mailbag: Genentech

Biotech-Stock Mailbag: Genentech

If Roche is serious about buying the company, it will need to do much better than $89 a share.

Feuerstein's Biotech-Stock Mailbag: Titan

Feuerstein's Biotech-Stock Mailbag: Titan

Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.

Biotech Stocks Regain Some Lost Ground

Biotech Stocks Regain Some Lost Ground

Stocks in the sector are trading higher Friday, following a mysterious final-hour bludgeoning Thursday that left many in the red.

TSC Ratings' Updates: ImClone

ImClone, Kyocera, Altria upgraded; Anadarko, Wesco downgraded.

Health Winners & Losers: Elan

Pharmaceutical makers outpaced biotech stocks on Monday.

Icahn Knocks Bristol's Bid for ImClone

Icahn Knocks Bristol's Bid for ImClone

The chairman is opposed to the takeover bid and questions how much Bristol knew of ImClone's potential plan to split.

Health Winners & Losers: Biogen

Health Winners & Losers: Biogen

Biogen sinks on Tysabri-related news.

Analysts' Upgrades, Downgrades: Akamai

Analysts' Upgrades, Downgrades: Akamai

See who made what calls.

'Fast Money' Recap: Exxon Marks the Spot

'Fast Money' Recap: Exxon Marks the Spot

The trading panel had differing opinions about where this oil giant is going.

ImClone Soars on Buyout Bid (Update2)

ImClone Soars on Buyout Bid (Update2)

ImClone says it's 'studying the situation' after receiving a $60-per-share bid from Bristol-Myers.

GDP Data Frighten Bulls Away

GDP Data Frighten Bulls Away

Dour GDP and employment reports kept stocks down Thursday, with all three major indices closing in the red. Hear David Peltier, Dan Fitzpatrick, Robert Holmes and Adam Feuerstein give their takes on what moved the market.

Health Winners & Losers: ImClone

Health Winners & Losers: ImClone

ImClone soars on a buyout bid.

ImClone Soars on Buyout Bid (Update)

ImClone Soars on Buyout Bid (Update)

The stock soars well above the $60 that Bristol-Myers is offering.

Biotech Stocks Burn Higher on M&A Fire

Biotech Stocks Burn Higher on M&A Fire

The sector is trading higher on today's buyout bid. One analyst offers a list of who else could tie the knot in the drug and biotech space.

Bristol-Myers Offers $60/Share for ImClone

ImClone shares are soaring on news of the $4.5 billion cash bid.

ImClone Hits Profit Target

Second-quarter revenue increases 11%.

Health Winners & Losers: St. Jude

St. Jude climbs on raised guidance.

Introgen's Advexin Doesn't Work. Period.

Introgen's Advexin Doesn't Work. Period.

Last week's conference call did nothing to assure investors that the gene therapy drug for head and neck cancer can secure regulatory approval.

Feuerstein's Biotech-Stock Mailbag: Delcath

Feuerstein's Biotech-Stock Mailbag: Delcath

More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.

Health Winners & Losers: Maxygen

Health Winners & Losers: Maxygen

Maxygen slides on news Amgen was granted a patent that may affect Maxygen's MAXY-G34, a possible treatment for chemotherapy-induced neutropenia.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The first post-ASCO mailbag includes questions on ImClone, Peregrine, GenVec, Ariad and more.

Health Winners & Losers: ImClone

Health Winners & Losers: ImClone

ImClone falls as investors digest ASCO data.

After ASCO, Whither ImClone?

After ASCO, Whither ImClone?

The attention paid to Erbitux misses a large factor in the lung cancer realm.

Gene Status Key in Erbitux vs. Colon Cancer

Patients with a normal KRAS gene benefit the most from Erbitux plus chemo. But those with a mutated form of the gene receive no benefit from the ImClone drug.

FLEX: Erbitux Boosts Survival Five Weeks

FLEX: Erbitux Boosts Survival Five Weeks

The much-anticipated lung cancer study shows ImClone's drug increases survival in lung cancer patients, but the results just meet statistical significance.